DOCSLIB.ORG

Optumrx Brand Pipeline Forecast

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Optumrx Brand Pipeline Forecast RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy PO Filed NDA 3/1/2019 Y N agonist NMDA receptor Major depressive esketamine esketamine Janssen Intranasal Filed NDA 3/8/2019 N N antagonist disorder (MDD) prostaglandin agonist/ latanoprost/ rho kinase- Glaucoma/ Ocular Roclatan Aerie OP Filed NDA 3/14/2019 N N netarsudil mesylate norepinephrine transport hypertension protein inhibitor HER2/neu receptor Herceptin trastuzumab Halozyme Breast cancer SC Filed BLA 3/15/2019 Y N antagonist gamma aminobutyric allopregnanolone acid-A (GABA-A) Postpartum SAGE-547 SAGE/ Ligand IV Filed NDA 3/19/2019 Y Y (brexanolone) receptor allosteric depression/ Seizures modulator Jazz Narcolepsy/ Sleep ADX-N05 solriamfetol Pharmaceuticals/ phenylalanine derivative PO Filed NDA 3/20/2019 N Y apnea Aerial BioPharma mometasone corticosteroid/ GSP-301 furoate/ Glenmark Allergic rhinitis NA Filed NDA 3/21/2019 N N antihistamine olopatadine HCl sodium-dependent glucose transporter 1 Zynquista sotagliflozin Sanofi/ Lexicon Diabetes mellitus PO Filed NDA 3/22/2019 N N (SGLT-1) and SGLT-2 inhibitor fosphenytoin fosphenytoin sodium/ sodium/ sulfobutylether sulfobutylether Sedor anticonvulsant Seizures IM/IV Filed NDA 3/22/2019 Y N beta- beta-cyclodextrin cyclodextrin sodium sodium nonsteroidal anti- Recro Pharma/ N-1539 meloxicam inflammatory drug Pain IV Filed NDA 3/24/2019 Y N Alkermes (NSAID) optum.com/optumrx 2 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug NRL-1 diazepam Neurelis benzodiazepine Seizures Intranasal Filed NDA 3/25/2019 N Y long-acting muscarinic acetylcholine receptor Chronic obstructive aclidinium/ AstraZeneca/ (mAChR) Duaklir Pressair pulmonary disease INH Filed NDA 3/31/2019 N N formoterol Actavis/ Circassia antagonist/long-acting (COPD) beta 2 agonist (LAMA/LABA) AMG-504-1 glucagon Eli Lilly/ Locemia glucagon analog Diabetes mellitus Intranasal Filed NDA 2Q2019 N N Rizaport IntelGenx / Red Hill rizatriptan triptans Acute migraines PO Filed NDA 4/1/2019 N N (VersaFilm) Biopharma EVK-001 metoclopramide Evoke Pharma antidopiminergics Diabetic gastroparesis Intranasal Filed NDA 4/1/2019 N Y Primary immunodeficiency/ RI-002 RI-002 ADMA Biologics immunoglobulin Respiratory syncytial IV Filed BLA 4/2/2019 Y N virus (RSV)/ Bacterial infections Multiple myeloma/ Sarcoma/ Diffuse large Karyopharm selective inhibitor of B-cell lymphoma KPT-330 selinexor PO Filed NDA 4/6/2019 Y Y Therapeutics nuclear export (SINE) (DLBCL)/ Acute myeloid leukemia (AML) calcitonin gene-related Aimovig (140 Filed erenumab-aooe Amgen peptide (CGRP) Migraine headaches SC 4/15/2019 N N mg dose) sNDA receptor antagonist Human dolutegravir/ GlaxoSmithKline/ Tivicay/ Epivir integrase inhibitor/ NRTI immunodeficiency virus PO Filed NDA 4/18/2019 Y N lamivudine Shionogi (HIV) Psoriasis/ Crohn's BI-655066 Boehringer interleukin-23 (IL-23) risankizumab disease/ Ankylosing IV/SC Filed BLA 4/25/2019 Y Y (ABBV-066) Ingelheim/ AbbVie inhibitor spondylitis/ Asthma optum.com/optumrx 3 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug Nabriva Contepo fosfomycin cell wall inhibitor Bacterial infections IV Filed NDA 4/30/2019 Y N Therapeutics anesthetic/ Nonsteroidal bupivacaine/ HTX-011 Heron Therapeutics Anti-inflammatory Drug Pain Instillation Filed NDA 4/30/2019 N N meloxicam (NSAID) Dengue fever Dengvaxia Sanofi Pasteur vaccine Dengue fever SC Filed BLA 5/1/2019 N N vaccine onasemnogene Spinal muscular Zolgensma Novartis/ Regenxbio gene therapy IV Filed BLA 5/1/2019 Y Y abeparvovec atrophy (SMA) dopamine receptor APD-421 amisulpride Acacia Nausea/ Vomiting IV Filed NDA 5/5/2019 N N antagonist FLT-3 receptor tyrosine Acute myeloid quizartinib quizartinib Daiichi Sankyo PO Filed NDA 5/25/2019 Y Y kinase inhibitor leukemia (AML) Slinda drospirenone Exeltis progesterone Pregnancy prevention PO Filed NDA 5/27/2019 N N NKTR-181 NKTR-181 Nektar opioid agonist Pain PO Filed NDA 5/28/2019 N N Imvamune; Imvamune; MVA- Bavarian Nordic vaccine Smallpox SC Filed BLA 6/1/2019 Y N MVA-BN BN osmotic gradient Bronchitol mannitol Pharmaxis enhancer; mucus Asthma/ Cystic fibrosis INH Filed NDA 6/20/2019 N Y clearance enhancer melanocortin type 4 Female sexual disorder PT-141 bremelanotide Palatin/ AMAG SC Filed NDA 6/23/2019 Y N receptor agonist (FSD) alpha-2/beta-1 vascular Ehlers-Danlos Edsivo celiprolol HCl Acer Therapeutics PO Filed NDA 6/25/2019 Y Y adrenergic agent Syndrome (vEDS) Thiola tiopronin Retrophin reducing agent Cystinuria PO Filed NDA 6/30/2019 N N human Ryplazim ProMetic/ Hematech plasminogen Plasminogen deficiency IV Filed BLA Mid-2019 Y Y plasminogen tadalafil phosphodiesterase-5 tadalafil VersaFilm IntelGenx Erectile dysfunction PO Filed NDA Mid-2019 Y N VersaFilm (PDE-5) inhibitor optum.com/optumrx 4 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug sphingosine 1- phosphate 1 (S1PR1) Multiple sclerosis/ RPC-1063 ozanimod Celgene PO CRL 3Q2019 Y N and 5 (S1PR5) receptor Ulcerative colitis (UC) modulator TRV-130 oliceridine Trevena opioid receptor agonist Pain IV CRL 3Q2019 N N astodrimer sodium VivaGel Starpharma viral attachment inhibitor Bacterial infections VG CRL 2H2019 N N (SPL-7013) Zalviso sufentanil, ARX-01 AcelRx opioid analgesic Pain SL CRL 2H2019 Y N Breast cancer/ Pancreatic cancer/ Pancreatic cancer/ Small cell lung cancer sacituzumab Immunomedics/ RS7-SN-38 antibody- IMMU-132 (SCLC)/ Non-small cell IV CRL 2H2019 Y Y govitecan Royalty Pharma drug conjugate lung cancer (NSCLC)/ Colorectal cancer/ Esophageal cancer/ Urinary bladder cancer Intracerebral/ FastTrk/ VTS-270 kleptose Sucampo/ INDPA sugar molecule Niemann-Pick disease 2H2019 Y Y Intrathecal Breakthru phosphoinositide 3- Breast cancer/ Head BYL-719 alpelisib Novartis kinase CA (PIK3CA) PO InTrial 2H2019 Y N and neck cancer inhibitor MNK-812 oxycodone Mallinckrodt opioid agonist Pain PO CRL 2H2019 N N Clostridium difficile Filed Vancocin vancomycin HCl ANI antibacterial infection (CDI)/ PO 7/1/2019 N N sNDA Enterocolitis optum.com/optumrx 5 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug Amyloid tafamidis cardiomyopathy/ amyloid accumulation Vyndaqel meglumine Pfizer Familial amyloid PO Filed NDA 7/1/2019 Y Y inhibitor polyneuropathy (FAP)/ Cardiomyopathy Erythropoietic protoporphyria (EPP)/ melanocortin receptor 1 Scenesse afamelanotide Clinuvel Polymorphous light SC Filed NDA 7/8/2019 Y Y (MC-1) agonist eruption (PLE/PMLE)/ Vitiligo Amyotrophic lateral Portage/ Biohaven/ glutamate release sclerosis (ALS)/ SL/ BHV-0223 riluzole Filed NDA 7/15/2019 N Y Catalent inhibitor Migraines/ Social Transmucosal anxiety disorder beta-lactamase inhibitor/ relebactam/ carbapenem/ MK-7655 imipenem/ Merck Bacterial infections IV Filed NDA 7/16/2019 Y N dehydropeptidase-1 cilastatin inhibitor Shield Therapeutics/ Anemia/ Irritable bowel Feraccru ferric trimaltol AOP Orphan iron replacement PO Filed NDA 7/23/2019 N N syndrome (IBS) Pharma Non-small cell lung cancer (NSCLC)/ FastTrk/ entrectinib entrectinib Ignyta tyrosine kinase inhibitor Colorectal cancer/ PO 8/1/2019 N Y Breakthru Solid tumors/ Neuroblastoma Tenosynovial giant cell selective macrophage PLX108-01 tumor (TGCT)/ pexidartinib Daiichi Sankyo colony stimulating factor PO Filed NDA 8/3/2019 N Y (PLX-3397) Pigmented Villonodular 1 receptor inhibitor Synovitis (PVNS) Dravet syndrome/ serotonin receptor Fintepla fenfluramine Zogenix Lennox-Gastaut PO Filed NDA 8/6/2019 Y Y agonist syndrome (LGS) optum.com/optumrx 6 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status
Load more

Recommended publications
  • Antineoplastic Agents
    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Pharmacy Policy Antineoplastic Agents Policy Number: 9.700 Version Number: 2.0 Version Effective Date: 9/1/2021 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth- MCO MassHealth- ACO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Note: Disclaimer and audit information is located at the end of this document. Prior Authorization Policy Products Affected: Daurismo™ (glasdegib tablet) Rubraca™ (rucaparib tablets) Erleada™ (apalutamide tablet) Sarclisa® (Isatuximab–IRFC injection) Farydak® (panobinostat capsule) Tazverik™ (tazemetostat tablet) Folotyn® (pralatrexate injection) Talzenna® (talazoparib capsule) Gleostine™ (lomustine capsule) Tibsovo® (ivosidenib tablet) Idhifa® (enasidenib mesylate tablet) Ukoniq (umbralisib tosylate tablet) Lonsurf® (tipiracil hcl and trifluridine tablet) Valchlor™ (mechlorethamine gel) Lynparza™ (olaparib capsule, and tablets) Zejula™ (niraparib capsules) Ninlaro® (ixazomib capsule) Zelboraf® (vemurafenib tablet) Odomzo® (sonidegib capsules) Zytiga® (abiraterone acetate tablet) Pomalyst® (pomalidomide capsule) + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. Antineoplastic Agents 1 of 4 The Plan may authorize coverage of the above products for members meeting the following criteria: Covered FDA approved indication Use Use supported by: o American Hospital Formulary Service Drug Information o DRUGDEX Information System o United States Pharmacopeia- Drug Information o National Comprehensive Cancer Network (categories 1,2a, and 2b) Medically accepted indications will also be considered for approval.
    [Show full text]
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
    Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept trial Sporadic inclusion body myositis (IBM) is the commonest idiopathic inflammatory myopathy (IIM) occurring in patients over the age of 50 years.1-4 The prevalence of IBM differs between different populations and ethnic groups, with estimates between 4.9-70.6 per million population.5-10 IBM is distinguished from the other IIM by early asymmetric finger flexor and knee extensor weakness (leading to loss of hand function and propensity to fall) and resistance to immunosuppressive therapy. Any skeletal muscle can be affected, including oesophageal and pharyngeal muscles. Late-stage disease can be characterized by very significant morbidity including disability and loss of quality of life. Death in IBM is related to malnutrition, cachexia, aspiration, respiratory infection and respiratory failure, as a consequence of dysphagia, severe global weakness and weakness of the respiratory muscles.1-4 In a Dutch cohort, end-of-life care interventions were used by 13% of patients with IBM, highlighting the morbidity experienced by these patients and the need of supportive and palliative care in this disease.2 The aetiopathogenesis of IBM remains uncertain. The varied pathological findings observed have driven a number of theories including viral infection, accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic reticulum stress and impairment of autophagy and proteasomal proteolysis.11-15 Muscle biopsies from patients with IBM typically show several different pathological features broadly described as inflammatory or degenerative. Inflammatory features include endomysial infiltration by mononuclear cells (predominantly CD8+ T- cells), which surround and invade otherwise normal appearing muscle fibres, and overexpression of major histocompatibility complex (MHC) class I, which is not constitutively expressed by skeletal muscle.
    [Show full text]
  • PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1
    Self-Administered Oncology Agents Through Preferred Prior Authorization Program Summary FDA APPROVED INDICATIONS3-104 Please reference individual agent product labeling. CLINICAL RATIONALE For the purposes of the Self -Administered Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation, AHFS, or DrugDex with level of evidence of 1 or 2A. SAFETY3-104 Agent(s) Contraindication(s) Afinitor/Afinitor Disperz Hypersensitivity to everolimus, to other rapamycin (everolimus) derivatives None Alecensa (alectinib) Alunbrig (brigatinib) None Ayvakit (avapritinib) None Balversa (erdafitinib) None Hypersensitivity to bosutinib Bosulif (bosutinib) Braftovi (encorafenib) None Brukinsa (zanubrutinib) None Cabometyx None (cabozantinib) Calquence None (acalabrutinib) Caprelsa Congenital long QT syndrome (vandetanib) Cometriq None (cabozantinib) Copiktra (duvelisib) None Cotellic (cobimetinib) None Daurismo (glasdegib) None None Erivedge (vismodegib) Erleada (apalutamide) Pregnancy None Farydak (panobinostat) Fotivda (tivozanib) None Gavreto (pralsetinib) None None Gilotrif (afatinib) Gleevec None (imatinib) Hycamtin Severe hypersensitivity to topotecan (topotecan) None Ibrance (palbociclib) KS_PS_SA_Oncology_PA_ProgSum_AR1020_r0821v2 Page 1 of 19 © Copyright Prime Therapeutics LLC. 08/2021 All Rights Reserved Effective: 10/01/2021 Agent(s) Contraindication(s) None Iclusig (ponatinib) Idhifa (enasidenib) None Imbruvica (ibrutinib)
    [Show full text]
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle
    Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Idaho Autism Summit November 2, 2019 Faculty Disclosure • Grants — Curemark, Roche, Otsuka • Advisory Board — Curemark, BioMarin, Janssen, Axial Biotherapeutics • Honoraria/Royalties: Oxford University Press, Taylor & Francis • Dr. Hendren does intend to discuss the use of off- label/unapproved use of drugs Learning Objectives • Identify successes and challenges in the developmental progression through the life cycle for people with developmental disabilities and their families • Identify and effectively treat comorbid medical, emotional and behavioral symptoms associated with autism spectrum disorders (ASD) • Consider integrating biomedical treatments for ASD including conventional psychotropic medication and what has been referred to as CAM/CIM into a comprehensive program. 2010 1 in 68; 2014 1 in 59 CDC Prevalence of Autism • Possible explanations include – Diagnostic expansion and substitution – Better reporting – Increased recognition – Increasing acceptability – Immigration for services – Environmental toxins – Infectious and immune vulnerability – Epigenetic processes Rutter M. Acta Pediatr. 2005;94(1):2-15. Centers for Disease Control and Prevention. Autism Spectrum Disorders. www.cdc.gov/ncbddd/autism. Accessed June 16, 2015. Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. ASD Genetic Etiology (Levels 1 & 2) • Multiple genes: NRXN12q, 7q11.23, 15q11-13, 16p11.2, SHANK 3, 2, NLGN4, MTHFR 677>T, SEMA5A, 2Q22.1, GRIN2B, 5P14.1, CDH9, 10, FRX, PTEN • Identical twins: 60% to 90% – Fraternal twins: 0% to 36% – Siblings: 4% to 19% • Clear genetic etiology accounts for 25% of autism cases • Hundreds of genetic mutations, some de novo, lead to many ways to develop and treat autism • Is Precision Medicine Possible? Weiss KM, Issues Science and Technology in 2017 Levy D, et al.
    [Show full text]
  • Pharmacological Management of Autism Spectrum Disorders
    Pharmacological Management of Autism Spectrum Disorders Lightin the Way 2018 David Ermer Md Pharmacotherapy common in Autism Spectrum iIlnesses (ASDs) ◼ 45% of children and adolescents with ASDs treated with psychotropic medications ◼ 75% of adults with ASDs treated with psychotropic medications Research into Psychotropic Medications in ASD’s is Relatively New ◼ Before 2006 there were no FDA approved medications for use in Autism ◼ With the increased incidence of ASDs being reported, there is increased interest from the pharmaceutical industry Treatment Strategies for Pharmacologic Intervention ◼ Pharmacologic treatments are available and significantly beneficial ◼ Educational and behavioral supports are the mainstays of treatment ◼ It is essential to integrate behavioral and pharmacologic treatments Realistic Expectations Must be Set ◼ Expectation that symptoms remit more quickly with pharmacologic treatment over behavioral treatments ◼ Expectation that response will be more complete with pharmacologic treatments ◼ “magic bullets” Must Optimize Environment ◼ Evaluate school setting ◼ Work with caregivers on home environment ◼ Pharmacologic strategies ineffective in unsupportive and inadequate environments Parental Collaboration is Essential ◼ Monitor patient and provide information to provider ◼ Administer medication ◼ Observe side effects ◼ Note emotional and behavioral effects ◼ Collaborate their information with school Focus on Symptom Clusters ◼ Most of the core symptoms are likely to remain ◼ Must focus on specific measurable symptoms
    [Show full text]
  • Reviews Insights Into Pathophysiology from Medication-Induced Tremor
    Freely available online Reviews Insights into Pathophysiology from Medication-induced Tremor 1* 1 1 1 John C. Morgan , Julie A. Kurek , Jennie L. Davis & Kapil D. Sethi 1 Movement Disorders Program Parkinson’s Foundation Center of Excellence, Department of Neurology, Medical College of Georgia, Augusta, GA, USA Abstract Background: Medication-induced tremor (MIT) is common in clinical practice and there are many medications/drugs that can cause or exacerbate tremors. MIT typically occurs by enhancement of physiological tremor (EPT), but not all drugs cause tremor in this way. In this manuscript, we review how some common examples of MIT have informed us about the pathophysiology of tremor. Methods: We performed a PubMed literature search for published articles dealing with MIT and attempted to identify articles that especially dealt with the medication’s mechanism of inducing tremor. Results: There is a paucity of literature that deals with the mechanisms of MIT, with most manuscripts only describing the frequency and clinical settings where MIT is observed. That being said, MIT emanates from multiple mechanisms depending on the drug and it often takes an individualized approach to manage MIT in a given patient. Discussion: MIT has provided some insight into the mechanisms of tremors we see in clinical practice. The exact mechanism of MIT is unknown for most medications that cause tremor, but it is assumed that in most cases physiological tremor is influenced by these medications. Some medications (epinephrine) that cause EPT likely lead to tremor by peripheral mechanisms in the muscle (b-adrenergic agonists), but others may influence the central component (amitriptyline).
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]